Trial Profile
Investigating the Release of Stored Enteral Lipids in Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Pharmacodynamics
- Acronyms GLP-2 Biopsy
- 18 May 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 03 Nov 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.